非静脉曲张性上消化道出血初次止血后应用止血粉预防再出血:多中心随机对照试验
这项前瞻性多中心随机对照试验纳入341例高风险病变非静脉曲张性上消化道出血且初次内镜止血成功的患者,1:1随机接受止血粉(Nexpowder)或不再进一步治疗。止血粉组72小时再出血率2.9%显著低于对照组11.3%(p=0.005),30天累积再出血率7.0% vs 18.8%,未报告与止血粉应用相关的不良事件。
要点
- 止血粉组72小时再出血率2.9%,显著低于对照组11.3%(p=0.005)。
- 止血粉组30天累积再出血率7.0%,对照组18.8%。
- 未报告与止血粉应用相关的不良事件。
核心结论
- 内镜止血后应用Nexpowder可显著降低非静脉曲张性上消化道出血患者的早期(3天)和晚期(30天)再出血率,尤其是溃疡相关出血。
研究设计与样本
- 前瞻性、多中心、随机对照试验,纳入初次内镜止血成功的急性非静脉曲张性上消化道出血高风险病变患者,1:1随机接受止血粉或不再进一步治疗(对照组)。
- 共纳入341例患者(72.1%男性;平均年龄64.8岁),止血粉组173例,对照组168例。
- 主要结局为治疗后72小时内再出血率;次要结局包括30天再出血率和安全性。
主要发现
- 72小时再出血率止血粉组为2.9%(95%CI 0.9至6.6%),对照组为11.3%(95%CI 6.9至17.1%),p=0.005。
- 30天累积再出血率止血粉组为7.0%,对照组为18.8%。
- 溃疡出血为主要病因(n=317),Forrest I型出血占三分之二。
- 溃疡亚组3天再出血率止血粉组为3.0%,对照组为12.0%,p=0.004。
- 未报告与止血粉应用相关的不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-variceal upper gastrointestinal bleeding (NVUGIB) remains a major cause of morbidity and mortality. Rebleeding rates following endoscopic treatment can reach up to 25% within 72 hours in patients with high-risk lesions. OBJECTIVE: To evaluate the efficacy of a haemostatic powder (Nexpowder) in reducing rebleeding rates after conventional endoscopic treatment in patients with NVUGIB. DESIGN: This was a prospective, multicentre, randomised controlled trial involving patients with acute NVUGIB from high-risk lesions who achieved initial endoscopic haemostasis. Participants were randomised 1:1 to receive either the haemostatic powder or no further therapy (control group). The primary outcome was the rebleeding rate within 72 hours post-treatment. Secondary outcomes included the 30-day rebleeding rate and the safety profile. RESULTS: A total of 341 patients (72.1% male; mean age 64.8 years) were included, with 173 in the powder group and 168 in the control group. Baseline characteristics were similar between groups. Ulcer bleeding was the predominant aetiology (n=317), with Forrest type I bleeding observed in two-thirds of cases. The 72-hour rebleeding rate was significantly lower in the powder group (2.9%, 95% CI 0.9 to 6.6%) compared with the control group (11.3%, 95% CI 6.9 to 17.1%; p =0.005). A significant reduction was also observed in the 30-day cumulative rebleeding rate (7.0% vs 18.8%), with similar findings in the ulcer subgroup for the 3-day rebleeding rate (3.0% vs 12.0%; p =0.004). No adverse events related to the powder application were reported. CONCLUSION: The application of Nexpowder following endoscopic haemostasis significantly reduced both early (3 days) and late (30 days) rebleeding rates in patients with NVUGIB, particularly in cases of ulcer-related bleeding. TRIAL REGISTRATION NUMBER: NCT04124588.
引用
- Shin J, Cha B, Hong J, et al. Prevention of rebleeding after primary haemostasis using haemostatic powder in non-variceal upper gastrointestinal bleeding: a multicentre randomised controlled trial. Gut. 2025. PMID: 40360231. doi:10.1136/gutjnl-2024-332459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。